Assessment of the acute effects of glucocorticoid treatment on coronary microembolization using cine, first-pass perfusion, and delayed enhancement MRI

Jin, Huajun; Yun, Hong; Ma, Jianying; Chen, Zhangwei; Chang, Shufu; Ge, Minghua; Zeng, Mengsu

doi:10.1002/jmri.25049

Cited by 1 publication

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also attenuated LV remodeling caused by microinfarct [67]. Jin et al [96] found a less decline in regional wall motion in the embolized area in animals treated with glucocorticoid (methylprednisone, as anti-inflammatory therapy) than control animals at 6 hrs after coronary microembolization. Methylprednisone administration ameliorated myocardial dysfunction (88.6% ± 7.6%) compared with control group (47.7% ± 4.7%; P < 0.001) at 6 hrs after embolization.…”

Section: Treatment Of Myocardial Microinfarctmentioning

confidence: 97%

Coronary Embolization and Myocardial Microinfarction: MR Imaging and Histopathologic Characterization

Saeed¹,

Hetts²,

Liang³

et al. 2016

IJCM

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) has been proven to reliably assess regional perfusion and left ventricular (LV) function of microembolized myocardium. The visibility of microinfarct on delayed enhancement MRI (DE-MRI) is limited and dependent on technical and biological issues. Furthermore, MRI underestimates total microinfarct size compared with microscopy. MRI studies revealed that the presence of microemboli in pre-existing acute infarct delays infarct healing and magnifies LV remodeling. Discrimination of acute from chronic microinfarct is based on presence of inflammatory cells, edema and scar tissue, respectively. These noninvasive findings highlight the importance of prognostic utility of MRI and warrant larger clinical studies or registries to evaluate the significance of presence of focal microinfarct. Serial microscopic studies revealed that intravascular microemboli migrate into the extravascular space and this migration process is a function of time. This phenomenon may limit the use of microemboli therapy in occluding hemorrhagic blood vessels or treating tumors. Despite current standard of care, existing methods and therapies do not prevent coronary embolization nor reverse their deleterious effects.

show abstract

Section: Treatment Of Myocardial Microinfarctmentioning

confidence: 97%